Similar observations were made in patients as reported by Mannweiler and colleagues in which PSMA expression was highly heterogeneous in many primary prostate tumors (7/51) and metastases (6/51), and was absent in 2 primary and 8 metastatic tumors (<10%) [129]. This evidence concerns the gene FOLH1 and metastatic neoplasm.